U.S. pharma huge copyright scrapped two experimental weight loss drugs last year—a at the time-every day pill, lotiglipron, as a result of elevated liver enzymes as well as a 2 times-every day pill, danuglipron, on account of strong Unwanted side effects—but CEO Albert Bourla has stated the company is set to “Participate in and acquire” in